Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …

Background The intestinal mucosa is composed of a well-organized epithelium, acting as a
physical barrier to harmful luminal contents, while simultaneously ensuring absorption of …

Around the world, about 15 to 40% of individuals with inflammatory bowel disease (IBD) rely
on cannabis and cannabinoids to reduce the need for other medications, as well as increase …

Cannabis is increasingly being used world-wide to treat a variety of dermatological
conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 …

Cannabinoids are increasingly-used substances in the treatment of chronic pain, some
neuropsychiatric disorders and more recently, skin disorders with an inflammatory …

Objective: We sought to quantify the anti-inflammatory effects of two cannabinoid drugs,
cannabidiol (CBD) and palmitoylethanolamide (PEA), in cultured cell lines and compared …

Recent studies have identified great similarities and interferences between the epithelial
layers of the digestive tract, the airways and the cutaneous layer. The relationship between …

Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis Sativa, has
garnered increasing attention for its diverse therapeutic potential. This comprehensive …

Background Clinical trials investigating the use of cannabinoid drugs for the treatment of
intestinal inflammation are anticipated secondary to preclinical literature demonstrating …

Intestinal inflammation is a chronic gastrointestinal disorder with uncertain pathophysiology
and causation that has significantly impacted both the physical and mental health of both …